Nuvation Bio Statistics
Total Valuation
Nuvation Bio has a market cap or net worth of $656.71 million. The enterprise value is $206.44 million.
Important Dates
The next estimated earnings date is Monday, August 4, 2025, before market open.
Earnings Date | Aug 4, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Nuvation Bio has 340.26 million shares outstanding. The number of shares has increased by 36.40% in one year.
Current Share Class | 339.26M |
Shares Outstanding | 340.26M |
Shares Change (YoY) | +36.40% |
Shares Change (QoQ) | +0.50% |
Owned by Insiders (%) | 24.88% |
Owned by Institutions (%) | 54.23% |
Float | 229.04M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 48.79 |
Forward PS | 22.37 |
PB Ratio | 1.45 |
P/TBV Ratio | 1.58 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 18.84 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.01, with a Debt / Equity ratio of 0.03.
Current Ratio | 9.01 |
Quick Ratio | 8.85 |
Debt / Equity | 0.03 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -522.44 |
Financial Efficiency
Return on equity (ROE) is -119.66% and return on invested capital (ROIC) is -25.08%.
Return on Equity (ROE) | -119.66% |
Return on Assets (ROA) | -23.33% |
Return on Invested Capital (ROIC) | -25.08% |
Return on Capital Employed (ROCE) | -46.93% |
Revenue Per Employee | $49,805 |
Profits Per Employee | -$2.76M |
Employee Count | 220 |
Asset Turnover | 0.02 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.45% in the last 52 weeks. The beta is 1.37, so Nuvation Bio's price volatility has been higher than the market average.
Beta (5Y) | 1.37 |
52-Week Price Change | -35.45% |
50-Day Moving Average | 2.15 |
200-Day Moving Average | 2.35 |
Relative Strength Index (RSI) | 44.77 |
Average Volume (20 Days) | 8,820,790 |
Short Selling Information
The latest short interest is 56.08 million, so 16.48% of the outstanding shares have been sold short.
Short Interest | 56.08M |
Short Previous Month | 37.83M |
Short % of Shares Out | 16.48% |
Short % of Float | 24.49% |
Short Ratio (days to cover) | 8.86 |
Income Statement
In the last 12 months, Nuvation Bio had revenue of $10.96 million and -$606.38 million in losses. Loss per share was -$2.03.
Revenue | 10.96M |
Gross Profit | 1.79M |
Operating Income | -206.36M |
Pretax Income | -510.72M |
Net Income | -606.38M |
EBITDA | -205.43M |
EBIT | -206.36M |
Loss Per Share | -$2.03 |
Full Income Statement Balance Sheet
The company has $461.68 million in cash and $11.41 million in debt, giving a net cash position of $450.26 million or $1.32 per share.
Cash & Cash Equivalents | 461.68M |
Total Debt | 11.41M |
Net Cash | 450.26M |
Net Cash Per Share | $1.32 |
Equity (Book Value) | 419.46M |
Book Value Per Share | 1.23 |
Working Capital | 422.80M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$157.34 million and capital expenditures -$207,000, giving a free cash flow of -$157.55 million.
Operating Cash Flow | -157.34M |
Capital Expenditures | -207,000 |
Free Cash Flow | -157.55M |
FCF Per Share | -$0.46 |
Full Cash Flow Statement Margins
Gross Margin | 16.29% |
Operating Margin | -1,883.38% |
Pretax Margin | -5,534.21% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Nuvation Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -36.40% |
Shareholder Yield | -36.40% |
Earnings Yield | -92.34% |
FCF Yield | -23.99% |
Analyst Forecast
The average price target for Nuvation Bio is $7.83, which is 305.70% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $7.83 |
Price Target Difference | 305.70% |
Analyst Consensus | Strong Buy |
Analyst Count | 6 |
Revenue Growth Forecast (5Y) | 128.28% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Nuvation Bio has an Altman Z-Score of 3.51 and a Piotroski F-Score of 1.
Altman Z-Score | 3.51 |
Piotroski F-Score | 1 |